Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Demographics | Age, sex, ethnicity, body weight and height | baseline |
| Age at Type 2 skin disease onset | Age of study patients at time of Type 2 skin disease onset | baseline |
| Type of current Type 2 skin disease therapy | Type of therapy administered to treat Type 2 skin disease (e.g., systemic, topical, other) | Baseline |
| Presence of Type 2 skin disease and selected comorbid conditions | Percentage of patients with Type 2 skin disease and selected comorbidities (e.g., asthma and allergic rhinitis) at baseline and during study | Baseline to Month 120 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies | Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies | Baseline to Month 120 |
| Eczema Area and Severity Index (EASI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with Type 2 skin disease. Estimated number of patients: 100,000 (No age limit)
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yang Wang, Doctor | Contact | 008613811232795 | yangwang_dr@bjmu.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University First Hospital | Recruiting | Beijing | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38431766 | Derived | Zhao J, Zhang Z, Chen H, Dou X, Zhao Z, Liu L, Wang Y, Li H. Associations of demographics, aggravating factors, comorbidities, and treatments with atopic dermatitis severity in China: A national cross-sectional study. Chin Med J (Engl). 2024 Mar 3;138(5):553-561. doi: 10.1097/CM9.0000000000003042. Epub 2024 Mar 3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
EASI score as assessed by physician |
| Baseline to Month 120 |
| Body Surface Area (BSA) percentage affected by Type 2 skin disease | BSA score as assessed by physician | Baseline to Month 120 |
| Patient Oriented Eczema Measure (POEM) questionnaire | POEM score as reported by the participant's caregiver | Baseline to Month 120 |
| Dermatology Life Quality Index | DLQI score as reported by the patients or caregivers | Baseline to Month 120 |
| Bullous Pemphigoid Disease Area Index(BPDAI) | BPDAI score as assessed by physician | Baseline to Month 120 |
| Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) | ABSIS score as assessed by physician | Baseline to Month 120 |
| Chronic Urticaria Quality of Life questionnaire (CU-Q2oL) | CU-Q2oL score as assessed by patients or caregivers | Baseline to Month 120 |
| Urticaria Activity Score 7a (UAS7a) | UAS7a score as assessed by physician | Baseline to Month 120 |
| Urticaria Control test (UCT) | UCT score as assessed by patients or caregivers | Baseline to Month 120 |